Xencor in Research and License Agreement with Roche's Genentech
February 05 2019 - 1:29PM
Dow Jones News
By Michael Dabaie
Xencor Inc. (XNCR) said Tuesday it has entered a research and
license agreement with Genentech, part of Roche (RHHBY).
Genentech will pay Xencor $120 million upfront, and Xencor will
be eligible to receive up to $180 million in development milestones
per program and profit share from commercialized medicines.
The deal aims to develop and commercialize novel IL-15 cytokine
therapeutics.
"We believe cytokine therapy will play an important role in the
treatment of a wide range of diseases, including cancer," said
James Sabry, global head of pharma partnering for Roche.
Xencor shares were recently up 4% to $37.88.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
February 05, 2019 13:14 ET (18:14 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Sep 2023 to Sep 2024